In late December, I recommended Vir Biotechnology, Inc. (NASDAQ:VIR) as a speculative Buy due to its long-term cash availability, experienced management team, collaborations with...
Palo Alto Networks has reassured analysts with its latest earnings report after a brief panic over its unusual timing. Its longer term growth guidance...